Results 71 to 80 of about 3,797 (199)
Possible retinotoxicity of long-term vardenafil treatment
Phosphodiesterase (PDE) inhibitors – such as vardenafil – are used primarily for treating erectile dysfunction via increasing cyclic guanosine monophosphate (cGMP) levels.
Lukáts, Ákos +13 more
core +1 more source
Food Science &Nutrition, Volume 13, Issue 6, June 2025.Erectile dysfunction (ED) is a common and debilitating condition that negatively impacts men's quality of life and psychological well‐being. Excessive circulating copper levels are causally linked to an increased risk of ED, as shown by Mendelian randomization and meta‐analysis. Balanced copper intake is crucial for sexual health, highlighting the need
Zilong Wang +6 more
wiley +1 more source
UroPrecision, Volume 3, Issue 2, Page 99-106, June 2025.Abstract Erectile dysfunction (ED) is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance, affecting over 50% of men aged 50 and older. ED is often linked to lifestyle factors and comorbidities, such as diabetes and cardiovascular disease.
Ahmed Ragheb
wiley +1 more source
Andrology, Volume 13, Issue 4, Page 794-803, May 2025.Abstract Background Cardiovascular disease induces erectile dysfunction modulated by endothelial nitric oxide synthase enzyme and an impaired ejection fraction that restricts penis vascular congestion. However, the mechanisms regulating endothelial dysfunction are not understood.
Ana Segura +7 more
wiley +1 more source
, 2015 Usama A Fahmy Department of Pharmaceutics & Industrial Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia Abstract: Vesicular drug delivery systems have recently gained attention as a way of improving dosing accuracy for ...
Fahmy UA
core
Classical activation of macrophages and vardenafil [PDF]
Clinical Science, 2017 Inhibitors of phosphodiesterase 5 (PDE5) – sildenafil citrate (Viagra; Pfizer) and vardenafil hydrochloride (Levitra; Bayer/GlaxoSmithKline) – approved for the treatment of erectile dysfunction and pulmonary arterial hypertension also rescue the loss of cystic fibrosis (CF) chloride channel function and the mislocalization of F508del-CFTR in affected ...
openaire +3 more sources
Vardenafil: update on clinical experience [PDF]
International Journal of Impotence Research, 2002 Vardenafil, a potent and selective phosphodiesterase 5 inhibitor, has entered phase 3 clinical trials. Pharmacodynamic studies showed that the maximum plasma concentration after oral administration of 20-40 mg of vardenafil occurred in 0.7-0.9 h, the half-life was 4-5 h, and negligible amounts remained in the circulation after 24 h.
openaire +2 more sources
Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan
Urological Science, 2016 Erectile dysfunction (ED) is a prevalent form of male sexual dysfunction. Phosphodiesterase type 5 (PDE5) inhibitor is the first-line treatment for ED. Numerous well-designed and -conducted clinical trials and postmarketing studies have established the ...
Bang-Ping Jiann
doaj +1 more source
The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral-electroencephalography study [PDF]
, 2013 Phosphodiesterase type 5 inhibitors (PDE5-Is) improve cognitive performance of rodents, but the few human studies investigating their effects did not systematically investigate cognitive effects and the results have been quite contradictory.
Steinbusch, H.W.M. +6 more
core +1 more source
Effects of vardenafil on intraocular pressure and orbital hemodynamics
, 2007 Batislam, Ertan/0000-0002-7493-4573\Purpose: The aim of this study was to investigate the effects of vardenafil on systemic blood pressure, intraocular pressure (IOP), and orbital hemodynamics.
Taner, Pelin +3 more
core +1 more source